EVALUATING MMP-2 AND TGFß-RI EXPRESSION IN CIRCULATING TUMOR CELLS OF PANCREATIC CANCER PATIENTS AND THEIR CORRELATION WITH CLINICAL EVOLUTION

Gasparini-Junior, José Luiz; Fanelli, Marcello Ferretti; Abdallah, Emne Ali; Chinen, Ludmilla Thomé Domingos

doi:10.1590/0102-672020190001e1433

Cited by 10 publications

(4 citation statements)

References 18 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Circulating Tumor Cells (CTCs) are released from primary tumor and/or metastatic sites into the bloodstream, are rare in the circulation and difficult to capture [71], furthermore, the rate of detection varies depending on the sampling site [72]. Studies on the prognostic role of CTCs yielded controversial results [73]; they have been more extensively studied for early detection of PDAC in asymptomatic subjects [74] or as a precocious marker of metastatic disease with different findings [75]. Most of the studies adopted different detection strategies, investigated small and non-homogeneous samples and used different end-points.…”

Section: Circurlating Tumor Dna and Circulating Tumor Cellsmentioning

confidence: 99%

Prognostic and predictive factors in pancreatic cancer

et al. 2020

View full text Add to dashboard Cite

Pancreatic cancer is one of the leading causes of cancer death worldwide. Its high mortality rate has remained unchanged for years. Radiotherapy and surgery are considered standard treatments in early and locally advanced stages. Chemotherapy is the only option for metastatic patients. Two treatment regimens, i. e. the association of 5-fluorouracil-irinotecan-oxaliplatin (FOLFIRINOX) and the association of nabpaclitaxel with gemcitabine, have been shown to improve outcomes for metastatic pancreatic adenocarcinoma patients. However, there are not standardized predictive biomarkers able to identify patients who benefit most from treatments. CA19-9 is the most studied prognostic biomarker, its predictive role remains unclear. Other clinical, histological and molecular biomarkers are emerging in prognostic and predictive settings. The aim of this review is to provide an overview of prognostic and predictive markers used in clinical practice and to explore the most promising fields of research in terms of treatment selection and tailored therapy in pancreatic cancer.

show abstract

Section: Circurlating Tumor Dna and Circulating Tumor Cellsmentioning

confidence: 99%

Prognostic and predictive factors in pancreatic cancer

et al. 2020

View full text Add to dashboard Cite

show abstract

“…29 MMP-2 and TGF-RI in the circulating tumour cells of PC patients are closely associated with disease severity. 30 Tumour cell MMP3 expression is a prognostic for poor survival in pancreatic, pulmonary and mammary carcinoma. 31 We therefore confirmed whether TP73-AS1 influenced the invasive ability of PC cells through its action on MMPs.…”

Section: Discussionmentioning

confidence: 99%

“…Stress‐induced phosphoprotein 1 promotes PC progression through its ability to activate FAK/AKT/MMP signalling 29 . MMP‐2 and TGF‐RI in the circulating tumour cells of PC patients are closely associated with disease severity 30 . Tumour cell MMP3 expression is a prognostic for poor survival in pancreatic, pulmonary and mammary carcinoma 31 .…”

Section: Discussionmentioning

confidence: 99%

LncRNA TP73‐AS1 enhances the malignant properties of pancreatic ductal adenocarcinoma by increasing MMP14 expression through miRNA ‐200a sponging

Miao

Guo

et al. 2021

J Cellular Molecular Medi

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) is an invasive and aggressive cancer that remains a major threat to human health across the globe. Despite advances in cancer treatments and diagnosis, the prognosis of PDAC patients remains poor. New and more effective PDAC therapies are therefore urgently required. In this study, we identified a novel host factor, namely the LncRNA TP73‐AS1, as overexpressed in PDAC tissues compared to adjacent healthy tissue samples. The overexpression of TP‐73‐AS1 was found to correlate with both PDAC stage and lymph node metastasis. To reveal its role in PDCA, we targeted TP73‐AS1 using LnRNA inhibitors in a range of pancreatic cancer (PC) cell lines. We found that the inhibition of TP73‐AS1 led to a loss of MMP14 expression in PC cells and significantly inhibited their migratory and invasive capacity. No effects of TP73‐AS1 on cell survival or proliferation were observed. Mechanistically, we found that TP73‐AS1 suppressed the expression of the known oncogenic miR‐200a. Taken together, these data highlight the prognostic potential of TP73‐AS1 for PC patients and highlight it as a potential anti‐PDAC therapeutic target.

show abstract

“…In a previous study by our group, [18] studied TGFß-RI expression in patients with pancreatic ductal adenocarcinoma and 16 patients were tested for TGFß-RI, 4 showing positive marking (25% of patients). There was no statistically signi cant difference in SLP between patients who showed positive marking for TGFß-RI compared to those who did not.…”

Section: Discussionmentioning

confidence: 99%

miR-203a-3p and MMP-2 protein are highly expressed in circulating tumor cells from patients with pancreatic carcinoma

Tarazona¹,

Abdallah²,

Flores³

et al. 2021

Preprint

Self Cite

View full text Add to dashboard Cite

Objectives: to explore the morphological, molecular and phenotypical characteristics of circulating tumor cells (CTCs) from blood of patients with pancreatic carcinoma, and to correlate the findings with response to treatment, progression-free survival, overall survival (OS) and deep vein thrombosis (DVT). Methods: peripheral blood (10mL) was analyzed before the beginning of treatment, and after 60 and 120 days. CTCs were detected by ISET® and characterized by immunocytochemistry. For miRNAs analysis, peripheral leukocytes from the same patients and healthy individuals (controls) were collected in parallel at baseline. The expression of miRNAs was evaluated (in pool) using TaqMan™ Array Human MicroRNA Cards v2.0. Results: there were included 9 patients. The proteins MMP2 and TGFβ-RI were highly expressed (77.7%) in CTCs at baseline; at the first follow-up, MMP2 was predominant (80%) and at second follow-up, MMP2 and vimentin were predominant (50%). Circulating tumor microemboli (CTM) were found in two patients and both presented DVT. The miR-203a-3p was highly expressed in CTCs. miR-203a-3p is involved in the stimulation of epithelial-to-mesenchymal transition (EMT) and related to worse OS in pancreatic cancer (TCGA data). Conclusion: Due to the low number of patients and short follow-up, we did not observe a correlation between CTCs and response to treatment. However, there was a correlation between CTM and DVT as also miR-203a-3p was highly expressed in CTCs, corroborating the findings of EMT proteins. This study opens perspectives concerning the dynamic change in the pattern of proteins expressed along treatment and the use of miRNAs as new targets in pancreatic carcinoma.

show abstract

EVALUATING MMP-2 AND TGFß-RI EXPRESSION IN CIRCULATING TUMOR CELLS OF PANCREATIC CANCER PATIENTS AND THEIR CORRELATION WITH CLINICAL EVOLUTION

Cited by 10 publications

References 18 publications

Prognostic and predictive factors in pancreatic cancer

Prognostic and predictive factors in pancreatic cancer

LncRNA TP73‐AS1 enhances the malignant properties of pancreatic ductal adenocarcinoma by increasing MMP14 expression through miRNA ‐200a sponging

miR-203a-3p and MMP-2 protein are highly expressed in circulating tumor cells from patients with pancreatic carcinoma

Contact Info

Product

Resources

About